Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial - Sadushi-Kolici, R; Jansa, P; Kopec, G (Lancet Respir Med, 2019)
et al.